Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2009

View Archived Issues

Fatostatin inhibits SREBP activation and reduces glucose levels and body weight in obese mice

DURATION-1 and -2 studies detail effects of once-weekly exenatide in type 2 diabetes

Listeria-based vaccine active against Her2/neu-expressing tumors in vivo

Double-blind trial shows potential of mycophenolate mofetil in pemphigus vulgaris

Randomized trial suggests preventive role of probucol in contrast-induced acute kidney injury

Sivelestat shows safety in clinical evaluation in IVIG-resistant Kawasaki disease

Dainippon Sumitomo and Sepracor complete tender offer

GDC-0941 to be evaluated in phase Ib trials in patients with advanced solid tumors

GSK and Prosensa sign collaboration for RNA-based therapeutics in DMD

Vaxin enters joint venture with AnC Bio for development of vaccines

Sosei assigns SD-281 drug discovery program to Biocopea

GSK withdraws centralized MAA for Zunrisa in postoperative nausea and vomiting

Phase II data show that QVA-149 is safe and improves bronchodilation in COPD

Ortho Clinical Diagnostics receives FDA approval for anti-HIV 1+2 test

BioSante completes its merger with Cell Genesys, will focus on LibiGel development

VEGFR, c-Raf and RET kinase inhibitors disclosed by MethylGene as oncolytics

Bristol-Myers Squibb claims 11beta-HSD1 inhibitors for diabetes and other conditions

Hepatitis C virus NS3 protease inhibitors described by Phenomix for HCV infection therapy

Merck & Co. claims angiotensin II receptor antagonists for the treatment of hypertension

Curemark enrolls first patients in phase III autism trial

Intercell starts European pivotal phase III trial for travelers' diarrhea vaccine

Lipsovir approved in Europe for recurrent herpes labialis

Otsuka acquires common shares of MethylGene

Oxigene to acquire VaxGen through stock-for-stock merger

Protalix presents topline results from phase III Uplyso trial

Sanofi Pasteur reports U.S. clinical trial results for its influenza A (H1N1) vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...